These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Vannam R; Sayilgan J; Ojeda S; Karakyriakou B; Hu E; Kreuzer J; Morris R; Herrera Lopez XI; Rai S; Haas W; Lawrence M; Ott CJ Cell Chem Biol; 2021 Apr; 28(4):503-514.e12. PubMed ID: 33400925 [TBL] [Abstract][Full Text] [Related]
63. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1. Cotton AD; Nguyen DP; Gramespacher JA; Seiple IB; Wells JA J Am Chem Soc; 2021 Jan; 143(2):593-598. PubMed ID: 33395526 [TBL] [Abstract][Full Text] [Related]
64. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. Alabi SB; Crews CM J Biol Chem; 2021; 296():100647. PubMed ID: 33839157 [TBL] [Abstract][Full Text] [Related]
65. The role of reversible and irreversible covalent chemistry in targeted protein degradation. Kiely-Collins H; Winter GE; Bernardes GJL Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091 [TBL] [Abstract][Full Text] [Related]
66. PROTACs: A Hope for Breast Cancer Patients? Kaur R; Chaudhary G; Kaur A; Singh P; Longowal GD; Sapkale GP; Arora S Anticancer Agents Med Chem; 2022; 22(3):406-417. PubMed ID: 33687888 [TBL] [Abstract][Full Text] [Related]
67. Novel PROTACs for degradation of SHP2 protein. Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076 [TBL] [Abstract][Full Text] [Related]
68. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy. Wang L; Shao X; Zhong T; Wu Y; Xu A; Sun X; Gao H; Liu Y; Lan T; Tong Y; Tao X; Du W; Wang W; Chen Y; Li T; Meng X; Deng H; Yang B; He Q; Ying M; Rao Y Nat Chem Biol; 2021 May; 17(5):567-575. PubMed ID: 33664520 [TBL] [Abstract][Full Text] [Related]
72. Advancing targeted protein degradation for cancer therapy. Dale B; Cheng M; Park KS; Kaniskan HÜ; Xiong Y; Jin J Nat Rev Cancer; 2021 Oct; 21(10):638-654. PubMed ID: 34131295 [TBL] [Abstract][Full Text] [Related]
73. Targeted protein degradation: A promise for undruggable proteins. Samarasinghe KTG; Crews CM Cell Chem Biol; 2021 Jul; 28(7):934-951. PubMed ID: 34004187 [TBL] [Abstract][Full Text] [Related]
74. Proximity-Based Modalities for Biology and Medicine. Liu X; Ciulli A ACS Cent Sci; 2023 Jul; 9(7):1269-1284. PubMed ID: 37521793 [TBL] [Abstract][Full Text] [Related]
75. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic. Hu Z; Crews CM Chembiochem; 2022 Jan; 23(2):e202100270. PubMed ID: 34494353 [TBL] [Abstract][Full Text] [Related]
76. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. Lu Y; Yang Y; Zhu G; Zeng H; Fan Y; Guo F; Xu D; Wang B; Chen D; Ge G Int J Biol Sci; 2023; 19(11):3360-3382. PubMed ID: 37496997 [TBL] [Abstract][Full Text] [Related]
77. A model-informed method to retrieve intrinsic from apparent cooperativity and project cellular target occupancy for ternary complex-forming compounds. Stein RR; Fouché M; Kearns JD; Roth HJ RSC Chem Biol; 2023 Jul; 4(7):512-523. PubMed ID: 37415863 [TBL] [Abstract][Full Text] [Related]
78. Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus. Xu Z; Liu X; Ma X; Zou W; Chen Q; Chen F; Deng X; Liang J; Dong C; Lan K; Wu S; Zhou HB Cell Insight; 2022 Jun; 1(3):100030. PubMed ID: 37193052 [TBL] [Abstract][Full Text] [Related]
79. The Ubiquitin-Proteasome System in Tumor Metabolism. Wang J; Xiang Y; Fan M; Fang S; Hua Q Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190313 [TBL] [Abstract][Full Text] [Related]
80. PROTACs in the Management of Prostate Cancer. Yedla P; Babalghith AO; Andra VV; Syed R Molecules; 2023 Apr; 28(9):. PubMed ID: 37175108 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]